Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is listed today as Dyne Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2020 | $116 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Dyne Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).
SEC Form D · Aug 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2020
Products and services#
No products or services of Dyne Therapeutics, Inc. are on record.
Investors#
22 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Atlas Venture Associates Opportunity I, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Atlas Venture Associates Opportunity I, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Atlas Venture Associates XI, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Atlas Venture Associates XI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Atlas Venture Fund XI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Atlas Venture Opportunity Fund I, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Catherine Stehman-Breen | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| CureDuchenne Ventures, LLC | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| David Charles Lubner | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Forbion Capital Fund IV Cooperatief U.A. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Lawrence Otto Klein | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Logos Global Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Asset Management Investors BV2018 LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioventures 2018 (B), L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2018 GP LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM BioVentures 2018 LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| MPM Bioventures 2018, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Vida Ventures II-A, LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Vida Ventures II, LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| VV Manager II, LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Largest shareholders today
Institutions holding Dyne Therapeutics, Inc. shares, as of Sep 30, 2026.
- T. Rowe Price Investment Management, Inc.$552 M18.29%
- BlackRock, Inc.$233 M7.72%
- Janus Henderson Group Ltd.$194 M6.43%
- FMR LLC$180 M5.95%
- Wellington Management Group LLP$170 M5.65%
- State Street Corp$131 M4.35%
- Vanguard Capital Management LLC$122 M4.03%
- Orbis Allan Gray Ltd$118 M3.91%
- Vestal Point Capital, LP$100 M3.31%
- Vanguard Portfolio Management LLC$76 M2.50%
- TCG Crossover Management, LLC$74 M2.46%
- Geode Capital Management, LLC$71 M2.35%
- Frazier Life Sciences Management, L.P.$62 M2.06%
- Price T Rowe Associates Inc /MD/$60 M1.99%
- Fcpm III Services B.V.$58 M1.91%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jonathan McNeill, M.D. | Executive officer | Aug 2020 |
| Joshua Brumm | Executive officer | Aug 2020 |
| Oxana Beskrovnaya, Ph.D. | Executive officer | Aug 2020 |
| Richard Scalzo | Executive officer | Aug 2020 |
| Romesh Subramanian, Ph.D. | Executive officer | Aug 2020 |
| Catherine Stehman-Breen, M.D. | Director | Aug 2020 |
| David Lubner | Director | Aug 2020 |
| Dirk Kersten | Director | Aug 2020 |
| Edward Hurwitz | Director | Aug 2020 |
| Jason Rhodes | Director | Aug 2020 |
| Joshua Brumm | Director | Aug 2020 |
| Lawrence Klein, Ph.D. | Director | Aug 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.